DelveInsight Business Research LLP

Albany, NY -- (SBWire) -- 10/25/2018 --DelveInsight has announced the addition of the "Osteosarcoma Market Insights, Epidemiology and Market Forecast-2027" drug pipelines to their offering.

The report provides an overview of the disease and market size of Osteosarcoma for the seven major markets i.e., United States, EU5 (France, Germany, Italy, Spain, UK) and Japan. The Report covers the overview, treatment practice and Osteosarcoma forecasted epidemiology from 2018 to 2027 segmented by seven major markets.
Osteosarcoma is the most common type of cancer that starts in the bones. In this case, the cancer cells in these tumors look like early forms of bone cells that normally help make new bone tissue, but the bone tissue in an osteosarcoma is not as strong as that of normal bones. Most tumors develop in the bones around the knee, either in the distal femur (the lower part of the thigh bone) or the proximal tibia (the upper part of the shinbone). Osteosarcoma is more common in males than in females.

Request for sample pages: https://www.delveinsight.com/dev-sample.php?form_name=Osteosarcoma---Market-Insight,-Epidemiology-and-Market-Forecast---2027

Most osteosarcomas occur in children and young adults between the ages of 10 and 30 in the United States. According to the American Cancer Society, 800 cases of osteosarcoma are diagnosed annually in the United States, which includes half children and teens. According to The European and American Osteosarcoma Study Group, the approximate annual incidence of osteosarcoma is 2-3 per million in Europe and America. The Current treatment methods used for Osteosarcoma include Surgery which remains the vital modality for treating the primary tumor, whereas Adjuvant Chemotherapy plays an essential role in the control of subclinical metastatic disease as several clinical trials are being done to determine the best combination of chemotherapy drugs. In certain cases, Radiation therapy is also deemed as an option. Other possible treatment options are based on various biologics and small molecules which have been used to target cell-surface receptors and downstream signaling pathways involved in OS pathogenesis. The PI3K/mTOR pathway and mitogen-activated protein kinases have also recently been recognized as potential targets and their therapeutic significance is currently under investigation.

Geography Covered

1. The United States
2. EU5 (Germany, France, Italy, Spain and the United Kingdom)
3. Japan

Study Period: 2016-2027
Drug Companies

1. Pfizer
2. Merck Sharp & Dohme
3. Jiangsu HengRui Medicine Co., Ltd
And many others

Drugs covered
1. Pembrolizumab
2. Apatinib
3. Avelumab
And many others

Report Scope

The report covers a descriptive overview of the Osteosarcoma, explaining its causes and currently available therapies. Comprehensive insight has been provided Osteosarcoma into the epidemiology of the Osteosarcoma and its treatment in the 7 MM, covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan. Additionally, an all-inclusive account of both the current and emerging therapies for Osteosarcoma are provided, along with assessment of the impact of new therapies will have on the current treatment landscape. A detailed review of global historical and forecasted Osteosarcoma market is included in the report, covering drug outreach in 7 MM. The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Osteosarcoma market.